February

March 19, 2012

Metabolomics, Proteomics, and Epigenetics

March 16, 2012

Why Oncologists Must Tailor Clinical Features to Their Needs

March 16, 2012

Promise and Pitfalls Along the Path to Personalized Care

March 16, 2012

The Duke Cancer Institute

March 16, 2012

To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.

March 16, 2012

Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.

March 16, 2012

How Much Do We Spend and How Can We Spend It Better?

March 12, 2012

Insights Into Value-Based Insurance Design in Oncology

March 12, 2012

Radical Changes in Payment Incentives and Elimination of Low-Value Care

March 12, 2012

Health Plans Continue to Seek Methods to Curtail Cancer Costs

March 12, 2012

Grim Reality Is a Bitter Pill to Swallow: Interview with Michael P. Link, MD, ASCO President

March 12, 2012

The Challenges Facing Oncologists Are Formidable

March 12, 2012

A New Era in Targeted Treatment Has Begun